NASDAQ : GLSI
Greenwich LifeSciences, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 19 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 278.89M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 2.36M | 2.23M | 2.16M | 1.63M | 1.56M | 1.04M |
| Research & Development | 20.30M | 17.22M | 15.48M | 7.70M | 6.48M | 3.56M |
| Operating Expenses | 22.66M | 19.45M | 17.64M | 9.33M | 8.04M | 4.60M |
| Operating Income | -22.66M | -19.45M | -17.64M | -9.33M | -8.04M | -4.60M |
| Interest & Investment Income | 186.64K | 89.70K | 223.01K | 436.06K | 215.02K | 27.37K |
| Pretax Income | -22.47M | -19.36M | -17.41M | -8.89M | -7.83M | -4.57M |
| Net Income | -22.47M | -19.36M | -17.41M | -8.89M | -7.83M | -4.57M |
| Net Income to Common | -22.47M | -19.36M | -17.41M | -8.89M | -7.83M | -4.57M |
| Shares Outstanding (Basic) | 14.24M | 13.53M | 13.01M | 12.85M | 12.91M | 12.94M |
| Shares Outstanding (Diluted) | 14.24M | 13.53M | 13.01M | 12.85M | 12.91M | 12.94M |
| EPS (Basic) | -1.58 | -1.43 | -1.34 | -0.69 | -0.61 | -0.35 |
| EPS (Diluted) | -1.58 | -1.43 | -1.34 | -0.69 | -0.61 | -0.35 |
| EBITDA | -22.66M | -19.45M | -17.63M | -9.32M | -8.04M | -4.59M |
| D&A For EBITDA | 890.00 | 1.78K | 3.61K | 3.61K | 3.61K | 3.61K |
| EBIT | -22.66M | -19.45M | -17.64M | -9.33M | -8.04M | -4.60M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 8.88M | 6.18M | 4.09M | 6.99M | 13.47M | 27.20M |
| Cash & Short-Term Investments | 8.88M | 6.18M | 4.09M | 6.99M | 13.47M | 27.20M |
| Total Current Assets | 8.88M | 6.18M | 4.09M | 6.99M | 13.47M | 27.20M |
| Other Intangible Assets | 1.78K | 5.39K | 9.00K | 12.62K | ||
| Total Assets | 8.88M | 6.18M | 4.09M | 6.99M | 13.48M | 27.22M |
| Accounts Payable | 4.81M | 4.65M | 2.58M | 35.47K | ||
| Accrued Expenses | 951.74K | 1.17M | 603.04K | 258.93K | 262.90K | 385.17K |
| Total Current Liabilities | 5.76M | 5.82M | 3.19M | 294.41K | 262.90K | 385.17K |
| Total Liabilities | 5.76M | 5.82M | 3.19M | 294.41K | 262.90K | 385.17K |
| Common Stock | 14.68K | 14.30K | 13.15K | 12.85K | 12.85K | 13.15K |
| Additional Paid-In Capital | 99.85M | 87.48M | 68.67M | 57.05M | 54.67M | 60.47M |
| Retained Earnings | -96.74M | -87.14M | -67.78M | -50.36M | -41.47M | -33.65M |
| Total Common Equity | 3.12M | 353.22K | 908.63K | 6.70M | 13.21M | 26.83M |
| Shareholders' Equity | 3.12M | 353.22K | 908.63K | 6.70M | 13.21M | 26.83M |
| Total Liabilities & Equity | 8.88M | 6.18M | 4.09M | 6.99M | 13.48M | 27.22M |
| Net Cash (Debt) | 8.88M | 6.18M | 4.09M | 6.99M | 13.47M | 27.20M |
| Net Cash Per Share | 0.62 | 0.46 | 0.31 | 0.54 | 1.04 | 2.10 |
| Filing Date Shares Outstanding | 14.68M | 14.68M | 13.27M | 12.88M | 12.85M | 12.95M |
| Total Common Shares Outstanding | 14.68M | 14.30M | 13.15M | 12.85M | 12.85M | 13.15M |
| Working Capital | 3.12M | 353.22K | 906.85K | 6.70M | 13.21M | 26.82M |
| Book Value Per Share | 0.21 | 0.02 | 0.07 | 0.52 | 1.03 | 2.04 |
| Tangible Book Value | 3.12M | 353.22K | 906.85K | 6.70M | 13.21M | 26.82M |
| Tangible Book Value Per Share | 0.21 | 0.02 | 0.07 | 0.52 | 1.03 | 2.04 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -22.47M | -19.36M | -17.41M | -8.89M | -7.83M | -4.57M |
| Depreciation & Amortization | 1.78K | 3.61K | 3.61K | 3.61K | 3.61K | |
| Stock-Based Compensation | 6.74M | 6.80M | 7.25M | 2.38M | 1.74M | 660.58K |
| Change in Accounts Payable | 2.90M | 2.07M | 2.55M | 35.47K | -526.73K | |
| Change in Other Net Operating Assets | 341.76K | 568.12K | 344.11K | -3.97K | -122.27K | 141.57K |
| Operating Cash Flow | -12.49M | -9.91M | -7.27M | -6.48M | -6.20M | -4.29M |
| Short-Term Debt Repaid | -275.15K | |||||
| Total Debt Repaid | -275.15K | |||||
| Net Debt Issued (Repaid) | -275.15K | |||||
| Issuance of Common Stock | 18.24M | 12.00M | 4.37M | 3.36M | ||
| Repurchase of Common Stock | -7.54M | |||||
| Other Financing Activities | -252.00K | |||||
| Financing Cash Flow | 18.24M | 12.00M | 4.37M | -7.54M | 2.84M | |
| Net Cash Flow | 5.75M | 2.09M | -2.90M | -6.48M | -13.74M | -1.46M |
| Levered Free Cash Flow | -3.34M | -2.71M | -875.59K | -3.42M | -3.40M | -2.59M |
| Unlevered Free Cash Flow | -3.34M | -2.71M | -875.59K | -3.42M | -3.40M | -2.59M |
| Change in Working Capital | 3.24M | 2.64M | 2.89M | 31.50K | -122.27K | -385.17K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 255.55M | 291.08M | 147.61M | 135.16M | 195.29M | 319.29M |
| Enterprise Value | 246.67M | 287.28M | 141.79M | 126.02M | 179.65M | 290.39M |
| Last Close Price | 17.41 | 21.01 | 11.23 | 10.52 | 15.20 | 24.33 |
| PB Ratio | 81.99 | 824.09 | 162.46 | 20.17 | 14.78 | 11.90 |
| P/TBV Ratio | 81.99 | 824.09 | 162.78 | 20.19 | 14.79 | 11.90 |
| Net Debt / Equity Ratio | -2.85 | -17.49 | -4.50 | -1.04 | -1.02 | -1.01 |
| Net Debt / EBITDA Ratio | 0.39 | 0.32 | 0.23 | 0.75 | 1.68 | 5.92 |
| Quick Ratio | 1.54 | 1.06 | 1.28 | 23.74 | 51.23 | 70.63 |
| Current Ratio | 1.54 | 1.06 | 1.28 | 23.74 | 51.23 | 70.63 |
| Return on Equity (ROE) | -986.32% | -3,068.25% | -457.73% | -89.30% | -39.08% | -16.78% |
| Return on Assets (ROA) | -235.98% | -236.67% | -198.82% | -56.95% | -24.70% | -10.28% |
| Return on Capital Employed (ROCE) | -726.90% | -5,505.90% | -1,941.10% | -139.20% | -60.80% | -17.10% |
| Earnings Yield | -9.07% | -6.65% | -11.80% | -6.58% | -4.01% | -1.43% |
| Buyback Yield / Dilution | -7.79% | -4.00% | -1.29% | 0.51% | 0.23% | -36.27% |